Oxford-AstraZeneca Vaccine: To treat the corona crisis epidemic, many companies worldwide are making the COVID 19 vaccine. Meanwhile Oxford University and AstraZeneca became the first vaccine manufacturer to have published the results of the final phase clinical trial. It is considered to be a major obstacle in the global race to produce safe and effective medicines for the treatment of corona virus. This research published in the health-related magazine Lancet has confirmed that the vaccine is effective in 70 percent of cases on average.
Increased hope of ending the epidemic
With the arrival of this report, there is now an increased hope that soon the vaccine will help in curbing the corona epidemic. Hopefully, this can help with the roll-out of the vaccine. Please tell that due to Corona virus epidemic, about 1.5 million people have died worldwide. Only in India the number of infected people is approaching 1 crore.
Compete against the corona virus
Andrew Pollard, director of the Oxford Vaccine Group, said that the publication in Lancet showed that the developers were sharing data transparently. He said that a series of vaccines would be needed to end the epidemic. If this does not happen, we will remain in the same position even after 6 months. He said that it is a competition against the corona virus, not the companies that make the vaccine.
Need more research now
Study shows that 62% effect was observed on giving 2 doses of vaccine. Whereas those who were given first half and then a full dose, this ratio was 90 percent. Research has confirmed that people older than 55 years were not included in this group of 1367 participants. However, its authors said that more research is needed.
Meanwhile, Britain on Tuesday became the first country to begin vaccination in Western countries, having used the vaccine developed by Pfizer-BioNTech after being approved for general use last week.
Source: www.financialexpress.com